Lithera appoints George Mahaffey as president and CEO
This article was originally published in Scrip
George Mahaffey has been named president and chief executive officer of Lithera; he will also join the company's board of directors. Dr John Dobak, founder and CEO of Lithera since its inception in 2007, will remain on the board of directors. Mr. Mahaffey has 24 years' pharmaceutical and biotechnology industry experience, having most recently served as CEO of Peplin after the dermatology company's acquisition by LEO Pharma in 2009. Lithera is a clinical-stage company developing pharmaceutical and biomedical products for medical and lifestyle indications in ophthalmology and aesthetic medicine. The company's lead injectable product candidate, LIPO-102, is designed to produce local, selective fat tissue reduction (pharmaceutical lipoplasty).